WebJul 8, 2016 · On Friday, July 8, 2016, a trademark application was filed for TEPI PATCH with the United States Patent and Trademark Office. The USPTO has given the TEPI PATCH trademark a serial number of 79191634. The federal status of this trademark filing is REGISTERED as of Tuesday, July 25, 2024. This trademark is owned by Medherant Ltd. WebOct 3, 2024 · The patent-protected patch technology enables the development of drug-in-adhesive patch products with better adhesion and more efficient delivery of drugs through the skin over a prolonged period. Medherant's first product, an ibuprofen TEPI Patch, is in Phase I clinical development with initial results expected in Q4 2024.
Medherant Announces Appointment Of New Chair BioSpace
WebFeb 14, 2024 · The global transdermal patch drug delivery system market is anticipated to record a CAGR of around 6.0% over the forecast period, i.e. 2024-2027 owing to increase in chronic diseases and growing awareness among the people. The painless application and non-invasive nature of transdermal patches, coupled with the rise in geriatric population … WebMay 21, 2024 · TEPI Patch technology can be used with a wider range of drugs, including those that are not suitable for oral administration. The amount of drug that can be loaded into the patch is greater, enabling the development of more effective transdermal therapies. adell mcgrath
Medherant completes successful study of TEPI Patch
WebNov 5, 2024 · The company has been developing transdermal drug delivery patches for pain and central nervous system diseases. The studies are the first clinical safety … WebNov 5, 2024 · The successful completion of these trials is a testament to our team’s hard work and dedication. We look forward to taking the Ibuprofen TEPI Patch into Phase III clinical testing.” Medherant is now seeking Series A finance to support the next phase of its Ibuprofen TEPI Patch study and to take its products into clinical development. WebOct 3, 2024 · TEPI Patch technology enables the development of drug-in-adhesive patch products “with better adhesion and more efficient delivery of drugs through the skin over a prolonged period,” according to the firm. Medherant's first product, an Ibuprofen TEPI Patch, is currently being assessed in Phase I clinical development with initial results ... adell live